MedTrace Logo

Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT05274633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-05-07

No results posted yet for this study

Summary

This study will collect clinical response data on participants who were already treated with eculizumab for at least 26 weeks and who started ravulizumab treatment as a specific therapeutic strategy as per ordinary clinical practice.

Conditions

Interventions

DRUG

Ravulizumab

Participants will be observed for 52 weeks after the start of ravulizumab.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-17
Primary Completion
2024-06-30
Completion
2025-03-24
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05274633 on ClinicalTrials.gov